Produktname:N-(4-Chloropyridin-2-yl)acetamide

IUPAC Name:N-(4-chloropyridin-2-yl)acetamide

CAS:245056-66-0
Molekulare Formel:C7H7ClN2O
Reinheit:98%
Katalognummer:CM171450
Molekulargewicht:170.6

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM171450-1g in stock ƴǫ
CM171450-5g in stock džȖȅ
CM171450-10g in stock ƚȤȤ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:245056-66-0
Molekulare Formel:C7H7ClN2O
Schmelzpunkt:-
SMILES-Code:CC(NC1=NC=CC(Cl)=C1)=O
Dichte:
Katalognummer:CM171450
Molekulargewicht:170.6
Siedepunkt:356°C at 760 mmHg
Mdl-Nr.:MFCD03394624
Lagerung:Store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Tasurgratinib
Eisai announced that it has obtained manufacturing and marketing approval for fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor ‘TASFYGO® Tablets 35mg’ (tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy. In Japan, it has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW), and the marketing authorization application was submitted in December 2023. TASFYGO is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.